{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:59:02Z","timestamp":1776286742180,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T00:00:00Z","timestamp":1414454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s11908-014-0448-3","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T06:45:44Z","timestamp":1414392344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Antibiotic-Induced Neurotoxicity"],"prefix":"10.1007","volume":"16","author":[{"given":"Shamik","family":"Bhattacharyya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Darby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron L.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"key":"448_CR1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-88-3-361","volume":"88","author":"S Frytak","year":"1978","unstructured":"Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978;88:361\u20132.","journal-title":"Ann Intern Med"},{"key":"448_CR2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00044011-200323070-00007","volume":"23","author":"G Maw","year":"2003","unstructured":"Maw G, Aitken P. Isoniazid overdose: a case series, literature review and survey of antidote availability. Clin Drug Investig. 2003;23:479\u201385.","journal-title":"Clin Drug Investig"},{"key":"448_CR3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3171\/jns.1993.78.6.0938","volume":"78","author":"TO Gr\u00f8ndahl","year":"1993","unstructured":"Gr\u00f8ndahl TO, Langmoen IA. Epileptogenic effect of antibiotic drugs. J Neurosurg. 1993;78:938\u201343.","journal-title":"J Neurosurg"},{"key":"448_CR4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00002018-199921020-00005","volume":"21","author":"H Lode","year":"1999","unstructured":"Lode H. Potential interactions of the extended-spectrum fluoroquinolones with the CNS. Drug Saf Int J Med Toxicol Drug Exp. 1999;21:123\u201335.","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"key":"448_CR5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00002018-200730080-00002","volume":"30","author":"P Linden","year":"2007","unstructured":"Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf Int J Med Toxicol Drug Exp. 2007;30:657\u201368.","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"key":"448_CR6","doi-asserted-by":"crossref","first-page":"92S","DOI":"10.1016\/0002-9343(89)90032-6","volume":"87","author":"GM Arcieri","year":"1989","unstructured":"Arcieri GM, Becker N, Esposito B, Griffith E, Heyd A, Neumann C, et al. Safety of intravenous ciprofloxacin. A review. Am J Med. 1989;87:92S\u20137S.","journal-title":"Am J Med"},{"issue":"Suppl 3","key":"448_CR7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000057843","volume":"47","author":"K Yagawa","year":"2001","unstructured":"Yagawa K. Latest industry information on the safety profile of levofloxacin in Japan. Chemotherapy. 2001;47 Suppl 3:38\u201343. discussion 44\u201348.","journal-title":"Chemotherapy"},{"issue":"Suppl A","key":"448_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/24.suppl_A.1","volume":"24","author":"RC Moellering Jr","year":"1989","unstructured":"Moellering Jr RC, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother. 1989;24(Suppl A):1\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"448_CR9","doi-asserted-by":"crossref","unstructured":"Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014","DOI":"10.1093\/jac\/dku111"},{"key":"448_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/27.4.405","volume":"27","author":"SE Schliamser","year":"1991","unstructured":"Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother. 1991;27:405\u201325.","journal-title":"J Antimicrob Chemother"},{"key":"448_CR11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.1967.tb50228.x","volume":"145","author":"PI Lerner","year":"1967","unstructured":"Lerner PI, Smith H, Weinstein L. Penicillin neurotoxicity. Ann N Y Acad Sci. 1967;145:310\u20138.","journal-title":"Ann N Y Acad Sci"},{"key":"448_CR12","unstructured":"Chang Y-M. Cefepime-induced nonconvulsive status epilepticus as a cause of confusion in an elderly patient: a case report. J Formos Med Assoc Taiwan Yi Zhi 2013"},{"key":"448_CR13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.54.2.340","volume":"54","author":"AR Towne","year":"2000","unstructured":"Towne AR, Waterhouse EJ, Boggs JG, Garnett LK, Brown AJ, Smith JR, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology. 2000;54:340\u20135.","journal-title":"Neurology"},{"key":"448_CR14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1756285611403826","volume":"4","author":"M Holtkamp","year":"2011","unstructured":"Holtkamp M, Meierkord H. Nonconvulsive status epilepticus: a diagnostic and therapeutic challenge in the intensive care setting. Ther Adv Neurol Disord. 2011;4:169\u201381.","journal-title":"Ther Adv Neurol Disord"},{"key":"448_CR15","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1345\/aph.1M296","volume":"43","author":"EE Mancl","year":"2009","unstructured":"Mancl EE, Gidal BE. The effect of carbapenem antibiotics on plasma concentrations of valproic acid. Ann Pharmacother. 2009;43:2082\u20137.","journal-title":"Ann Pharmacother"},{"key":"448_CR16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1345\/aph.1K079","volume":"41","author":"I Spriet","year":"2007","unstructured":"Spriet I, Goyens J, Meersseman W, Wilmer A, Willems L, Van Paesschen W. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007;41:1130\u20136.","journal-title":"Ann Pharmacother"},{"key":"448_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.amjopharm.2009.02.005","volume":"7","author":"J Gu","year":"2009","unstructured":"Gu J, Huang Y. Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient. Am J Geriatr Pharmacother. 2009;7:26\u201333.","journal-title":"Am J Geriatr Pharmacother"},{"key":"448_CR18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1001\/jama.1977.03270510052024","volume":"237","author":"JQ Rose","year":"1977","unstructured":"Rose JQ, Choi HK, Schentag JJ, Kinkel WR, Jusko WJ. Intoxication caused by interaction of chloramphenicol and phenytoin. J Am Med Assoc. 1977;237:2630\u20131.","journal-title":"J Am Med Assoc"},{"key":"448_CR19","first-page":"489","volume":"7","author":"NK O\u2019Connor","year":"1994","unstructured":"O\u2019Connor NK, Fris J. Clarithromycin-carbamazepine interaction in a clinical setting. J Am Board Fam Pract. 1994;7:489\u201392.","journal-title":"J Am Board Fam Pract"},{"key":"448_CR20","first-page":"513","volume":"43","author":"T Tagawa","year":"1989","unstructured":"Tagawa T, Mimaki T, Ono J, Tanaka J, Suzuki Y, Itagaki T, et al. Erythromycin-induced carbamazepine intoxication in two epileptic children. Jpn J Psychiatr Neurol. 1989;43:513\u20134.","journal-title":"Jpn J Psychiatr Neurol"},{"key":"448_CR21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1542\/peds.69.4.494","volume":"69","author":"SH Block","year":"1982","unstructured":"Block SH. Carbamazepine-isoniazid interaction. Pediatrics. 1982;69:494\u20135.","journal-title":"Pediatrics"},{"key":"448_CR22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ccc.2008.05.008","volume":"24","author":"JR Maldonado","year":"2008","unstructured":"Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin. 2008;24:657\u2013722. vii.","journal-title":"Crit Care Clin"},{"key":"448_CR23","first-page":"3","volume":"107","author":"A Bischoff","year":"1977","unstructured":"Bischoff A, Meier C, Roth F. Gentamicin neurotoxicity (polyneuropathy\u2013encephalopathy). Schweiz Med Wochenschr. 1977;107:3\u20138.","journal-title":"Schweiz Med Wochenschr"},{"key":"448_CR24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00415-009-5340-y","volume":"257","author":"J Fletcher","year":"2010","unstructured":"Fletcher J, Aykroyd LE, Feucht EC, Curtis JM. Early onset probable linezolid-induced encephalopathy. J Neurol. 2010;257:433\u20135.","journal-title":"J Neurol"},{"key":"448_CR25","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1542\/peds.2004-1352","volume":"115","author":"M Saidinejad","year":"2005","unstructured":"Saidinejad M, Ewald MB, Shannon MW. Transient psychosis in an immune-competent patient after oral trimethoprim-sulfamethoxazole administration. Pediatrics. 2005;115:e739\u2013741.","journal-title":"Pediatrics"},{"key":"448_CR26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0016-5085(94)90716-1","volume":"106","author":"GS Cooper","year":"1994","unstructured":"Cooper GS, Blades EW, Remler BF, Salata RA, Bennert KW, Jacobs GH. Central nervous system Whipple\u2019s disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime. Gastroenterology. 1994;106:782\u20136.","journal-title":"Gastroenterology"},{"key":"448_CR27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2125.2011.03991.x","volume":"72","author":"MF Grill","year":"2011","unstructured":"Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72:381\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"448_CR28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","volume":"34","author":"A Kuriyama","year":"2011","unstructured":"Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34:241\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"448_CR29","first-page":"313","volume":"18","author":"M Bandettini di Poggio","year":"2011","unstructured":"Bandettini di Poggio M, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci Off J Neurosurg Soc Australas. 2011;18:313\u20138.","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"448_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/0301-4738.77035","volume":"59","author":"P Sharma","year":"2011","unstructured":"Sharma P, Sharma R. Toxic optic neuropathy. Indian J Ophthalmol. 2011;59:137\u201341.","journal-title":"Indian J Ophthalmol"},{"key":"448_CR31","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4065\/78.11.1409","volume":"78","author":"A Melamud","year":"2003","unstructured":"Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc. 2003;78:1409\u201311.","journal-title":"Mayo Clin Proc"},{"key":"448_CR32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1442-9071.2007.01427.x","volume":"35","author":"N Samarakoon","year":"2007","unstructured":"Samarakoon N, Harrisberg B, Ell J. Ciprofloxacin-induced toxic optic neuropathy. Clin Exp Ophthalmol. 2007;35:102\u20134.","journal-title":"Clin Exp Ophthalmol"},{"key":"448_CR33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/FTD.0b013e3182480af4","volume":"34","author":"S Das","year":"2012","unstructured":"Das S, Mondal S. Oral levofloxacin-induced optic neuritis progressing in loss of vision. Ther Drug Monit. 2012;34:124\u20135.","journal-title":"Ther Drug Monit"},{"key":"448_CR34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.1980.01020040269011","volume":"98","author":"V Godel","year":"1980","unstructured":"Godel V, Nemet P, Lazar M. Chloramphenicol optic neuropathy. Arch Ophthalmol. 1980;98:1417\u201321.","journal-title":"Arch Ophthalmol"},{"key":"448_CR35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1442-9071.2007.01537.x","volume":"35","author":"NM McGrath","year":"2007","unstructured":"McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. Clin Exp Ophthalmol. 2007;35:585\u20136.","journal-title":"Clin Exp Ophthalmol"},{"key":"448_CR36","first-page":"877","volume":"20","author":"GP Stavern Van","year":"2014","unstructured":"Van Stavern GP. Metabolic, hereditary, traumatic, and neoplastic optic neuropathies. Continuum (Minneap Minn). 2014;20:877\u2013906.","journal-title":"Continuum (Minneap Minn)"},{"key":"448_CR37","first-page":"765","volume":"15","author":"S Lessell","year":"1976","unstructured":"Lessell S. Histopathology of experimental ethambutol intoxication. Invest Ophthalmol Vis Sci. 1976;15:765\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"448_CR38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3341\/kjo.1997.11.2.106","volume":"11","author":"SY Choi","year":"1997","unstructured":"Choi SY, Hwang JM. Optic neuropathy associated with ethambutol in Koreans. Korean J Ophthalmol. 1997;11:106\u201310.","journal-title":"Korean J Ophthalmol"},{"key":"448_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/bjo.2006.102541","volume":"91","author":"M Javaheri","year":"2007","unstructured":"Javaheri M, Khurana RN, O\u2019hearn TM, Lai MM, Sadun AA. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol. 2007;91:111\u20135.","journal-title":"Br J Ophthalmol"},{"key":"448_CR40","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/01.wnl.0000201313.24970.b8","volume":"66","author":"JC Rucker","year":"2006","unstructured":"Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS. Linezolid-associated toxic optic neuropathy. Neurology. 2006;66:595\u20138.","journal-title":"Neurology"},{"key":"448_CR41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11910-009-0011-z","volume":"9","author":"LH Weimer","year":"2009","unstructured":"Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2009;9:69\u201375.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"448_CR42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/B978-0-444-52902-2.00042-4","volume":"115","author":"H Manji","year":"2013","unstructured":"Manji H. Drug-induced neuropathies. Handb Clin Neurol. 2013;115:729\u201342.","journal-title":"Handb Clin Neurol"},{"key":"448_CR43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-2005-871329","volume":"25","author":"RW Pratt","year":"2005","unstructured":"Pratt RW, Weimer LH. Medication and toxin-induced peripheral neuropathy. Semin Neurol. 2005;25:204\u201316.","journal-title":"Semin Neurol"},{"key":"448_CR44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/08830738060210051201","volume":"21","author":"LD Hobson-Webb","year":"2006","unstructured":"Hobson-Webb LD, Roach ES, Donofrio PD. Metronidazole: newly recognized cause of autonomic neuropathy. J Child Neurol. 2006;21:429\u201331.","journal-title":"J Child Neurol"},{"key":"448_CR45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/archderm.1969.01610260090016","volume":"100","author":"AC Saqueton","year":"1969","unstructured":"Saqueton AC, Lorincz AL, Vick NA, Hamer RD. Dapsone and peripheral motor neuropathy. Arch Dermatol. 1969;100:214\u20137.","journal-title":"Arch Dermatol"},{"key":"448_CR46","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1592\/phco.27.8.1189","volume":"27","author":"M Narita","year":"2007","unstructured":"Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189\u201397.","journal-title":"Pharmacotherapy"},{"key":"448_CR47","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/AAC.00753-13","volume":"57","author":"MW Carroll","year":"2013","unstructured":"Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57:3903\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"448_CR48","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","volume":"40","author":"G Sotgiu","year":"2012","unstructured":"Sotgiu G, Centis R, D\u2019Ambrosio L, Alffenaar J-WC, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430\u201342.","journal-title":"Eur Respir J"},{"key":"448_CR49","first-page":"19","volume":"24","author":"EG Boyce","year":"1990","unstructured":"Boyce EG, Cookson ET, Bond WS. Persistent metronidazole-induced peripheral neuropathy. DICP Ann Pharmacother. 1990;24:19\u201321.","journal-title":"DICP Ann Pharmacother"},{"key":"448_CR50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","volume":"4","author":"AM Bressler","year":"2004","unstructured":"Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004;4:528\u201331.","journal-title":"Lancet Infect Dis"},{"key":"448_CR51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2230.1995.tb02672.x","volume":"20","author":"LE Rhodes","year":"1995","unstructured":"Rhodes LE, Coleman MD, Lewis-Jones MS. Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. Clin Exp Dermatol. 1995;20:155\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"448_CR52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1529-8027.2001.006001014.x","volume":"6","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst. 2001;6:14\u201320.","journal-title":"J Peripher Nerv Syst"},{"key":"448_CR53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8:475\u201390.","journal-title":"Lancet Neurol"},{"key":"448_CR54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archinte.1997.00440250045006","volume":"157","author":"ET Wittbrodt","year":"1997","unstructured":"Wittbrodt ET. Drugs and myasthenia gravis. An update. Arch Intern Med. 1997;157:399\u2013408.","journal-title":"Arch Intern Med"},{"key":"448_CR55","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bmj.1.5390.1111-b","volume":"1","author":"E Hokkanen","year":"1964","unstructured":"Hokkanen E. Antibiotics in myasthenia gravis. Br Med J. 1964;1:1111\u20132.","journal-title":"Br Med J"},{"key":"448_CR56","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0404.1964.tb02758.x","volume":"40","author":"E Hokkanen","year":"1964","unstructured":"Hokkanen E. The aggravating effect of some antibiotics on the neuromuscular blockade in myasthenia gravis. Acta Neurol Scand. 1964;40:346\u201352.","journal-title":"Acta Neurol Scand"},{"key":"448_CR57","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","volume":"34","author":"SC Jones","year":"2011","unstructured":"Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf Int J Med Toxicol Drug Exp. 2011;34:839\u201347.","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"key":"448_CR58","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4103\/0028-3886.53270","volume":"57","author":"S Pradhan","year":"2009","unstructured":"Pradhan S, Pardasani V, Ramteke K. Azithromycin-induced myasthenic crisis: reversibility with calcium gluconate. Neurol India. 2009;57:352\u20133.","journal-title":"Neurol India"},{"key":"448_CR59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/clinids\/22.1.175","volume":"22","author":"E Pijpers","year":"1996","unstructured":"Pijpers E, van Rijswijk RE, Takx-K\u00f6hlen B, Schrey G. A clarithromycin-induced myasthenic syndrome. Clin Infect Dis Off Publ Infect Dis Soc Am. 1996;22:175\u20136.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"448_CR60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-3476(05)81058-3","volume":"119","author":"JR Absher","year":"1991","unstructured":"Absher JR, Bale JF. Aggravation of myasthenia gravis by erythromycin. J Pediatr. 1991;119:155\u20136.","journal-title":"J Pediatr"},{"key":"448_CR61","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ana.410280417","volume":"28","author":"EF May","year":"1990","unstructured":"May EF, Calvert PC. Aggravation of myasthenia gravis by erythromycin. Ann Neurol. 1990;28:577\u20139.","journal-title":"Ann Neurol"},{"key":"448_CR62","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM197908233010805","volume":"301","author":"Z Argov","year":"1979","unstructured":"Argov Z, Mastaglia FL. Drug therapy: disorders of neuromuscular transmission caused by drugs. N Engl J Med. 1979;301:409\u201313.","journal-title":"N Engl J Med"},{"key":"448_CR63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(03)01319-0","volume":"461","author":"D Dobrev","year":"2003","unstructured":"Dobrev D, Ravens U. Therapeutically relevant concentrations of neomycin selectively inhibit P-type Ca2+ channels in rat striatum. Eur J Pharmacol. 2003;461:105\u201311.","journal-title":"Eur J Pharmacol"},{"key":"448_CR64","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.neuropharm.2009.07.031","volume":"57","author":"MT Harnett","year":"2009","unstructured":"Harnett MT, Chen W, Smith SM. Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness. Neuropharmacology. 2009;57:502\u20135.","journal-title":"Neuropharmacology"},{"key":"448_CR65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0006-8993(95)01349-0","volume":"712","author":"JP Sieb","year":"1996","unstructured":"Sieb JP, Milone M, Engel AG. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res. 1996;712:179\u201389.","journal-title":"Brain Res"},{"key":"448_CR66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/WNL.50.3.804","volume":"50","author":"JP Sieb","year":"1998","unstructured":"Sieb JP. Fluoroquinolone antibiotics block neuromuscular transmission. Neurology. 1998;50:804\u20137.","journal-title":"Neurology"},{"key":"448_CR67","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1128\/AAC.00840-10","volume":"54","author":"D Bertrand","year":"2010","unstructured":"Bertrand D, Bertrand S, Neveu E, Fernandes P. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob Agents Chemother. 2010;54:5399\u2013402.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-014-0448-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-014-0448-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-014-0448-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T17:55:56Z","timestamp":1650477356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-014-0448-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,28]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1007\/s11908-014-0448-3","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,28]]},"article-number":"448"}}